Cost-utility and Physiological Effects of ACT and BATD in Patients With Chronic Pain and Depression
Ключови думи
Резюме
Описание
The IMPACT Project's main objective is to determine the effectiveness of adding to the standard care of patients with chronic pain and mild to moderate major depression a group programme based on ACT or a group programme based on BATD and analyse the cost-utility of these psychological treatments from a health and social perspective. Likewise, both in chronic pain and in other usually associated psychiatric diseases, there is a ubiquitous lack of knowledge about what specific psychological and physiological mechanisms are modified by these third generation psychotherapies and how they relate to the observed clinical results. The potential predictors of response to these treatments are also unknown. In chronic musculoskeletal pain where central sensitization plays an important role, alterations have been found in different markers associated with an increased experience of pain. Some of these alterations in markers (e.g. high levels of pro-inflammatory cytokines) would also appear to be shared with other psychiatric diseases (major depression), a fact that would suggest a possible common mechanism involved in the etiopathogenesis of these diseases. Third generation psychotherapies have proven effective for pain management and regulation of the immune response. The IMPACT Multicentre Project (Improving Pain and Depression with ACT and BATD) will significantly expand the limited knowledge available about how ACT and BATD therapies exert their effects on relevant clinical improvement variables and will try to identify response predictive factors to these treatments.
Дати
| Последна проверка: | 02/29/2020 |
| Първо изпратено: | 10/21/2019 |
| Очаквано записване подадено: | 10/22/2019 |
| Първо публикувано: | 10/27/2019 |
| Изпратена последна актуализация: | 03/15/2020 |
| Последна актуализация публикувана: | 03/16/2020 |
| Действителна начална дата на проучването: | 04/30/2020 |
| Приблизителна дата на първично завършване: | 12/30/2021 |
| Очаквана дата на завършване на проучването: | 12/30/2022 |
Състояние или заболяване
Интервенция / лечение
Behavioral: TAU + Acceptance and Commitment Therapy (ACT)
Behavioral: TAU + Behavioral Activation Therapy for Depression (BATD)
Other: Treatment as Usual (TAU)
Фаза
Групи за ръце
| Arm | Интервенция / лечение |
|---|---|
| Experimental: TAU + Acceptance and Commitment Therapy (ACT) This therapy is based, as the name implies, on the acceptance (not avoidance) of negative experiences as a coping strategy, and on committing to life values or objectives. ACT has been used for various conditions, including chronic pain. Since avoidance is a strategy frequently used by patients suffering from pain, the application of this therapy seems very appropriate. In fact, it has been proven that patients who accept their pain more are those who score lower in pain intensity, have less negative emotions and enjoy a better quality of life. | Behavioral: TAU + Acceptance and Commitment Therapy (ACT) Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Presentation of the general concept of ACT therapy. Session 2: Value analysis I. Session 3: Value analysis II. Session 4: Value analysis III. Session 5: Values and feelings. Session 6: Taking a direction. Session 7: Dare and change. Session 8: Ready to act with ACT. |
| Experimental: TAU + Behavioral Activation Therapy for Depression (BATD) Behavioural and structured treatment based on the application of learning principles. Its objective is to counteract depressive symptoms and, as a consequence, to ensure that patients regain a productive and emotionally satisfying life. Its basic methodology consists in activating subjects with depression through programming and conduct of behaviours that are likely to increase the positive reinforcement of their context. | Behavioral: TAU + Behavioral Activation Therapy for Depression (BATD) Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Collection of information regarding areas of activity and interaction contexts.
Session 2: Identification of information related to depressive behaviours. Session 3 Obtaining complementary information regarding the characteristics of the history of patient interactions and any contexts.
Session 4: Explanation of the hypotheses of problematic behaviour, its maintenance and change throughout the intervention.
Session 5: Once the 10 target activities have been identified, a record is made to track and their progress weekly.
Session 6: Discussion of what was obtained from the records in general and of the satisfaction obtained, and explanation of the contexts and reinforcers.
Session 7: Psycho-education Session 8: New behaviours, the goals achieved and the maintenance of the weekly activity are inquired about. |
| Active Comparator: Treatment as Usual (TAU) Standard Care. Although there is no treatment considered as the gold standard for chronic pain and comorbid major depression, the standard treatment is usually mainly pharmacological and conforms to the symptomatic profile of each patient. |
Критерии за допустимост
| Възрасти, отговарящи на условията за проучване | 18 Years Да се 18 Years |
| Полове, допустими за проучване | All |
| Приема здрави доброволци | Да |
| Критерии | Inclusion Criteria: Patients who have been visited in the last 3 years in the participating centres and who have been given a diagnosis of chronic non-cancer musculoskeletal pain. In telephone screening, it will be evaluated whether the current pain intensity is at least moderate and PHQ-9 will be administered to confirm the presence of mild to moderate active depression. 1. Patients between 18 and 70 years of age. 2. Diagnosis of chronic pain (≥ 3 months) according to medical history (current pain ≥ 4 out of 10) 3. Diagnosis of mild to moderate depression according to PHQ-9 (score between 5 and 19). 4. Understanding of Spanish. 5. Access to a Smartphone (with Android operating system). 6. Written informed consent. Exclusion Criteria: 1. Presence of cognitive impairment according to MMSE (≤ 24 out of 30). 2. Previous (last year) or current psychological treatment. 3. Presence of severe mental disorder (e.g. psychotic disorder) related to substance dependence/abuse or another disease that affects the CNS (organic brain pathology or head trauma of any severity). 4. Presence of serious, uncontrolled or degenerative medical disease that may interfere with affective symptoms. 5. Risk of suicide (Item 9 score of PHQ-9 ≥ 2). 6. Patients involved in legal proceedings with employers in relation to their illness. 7. Patients with scheduled surgical intervention or other interventions. 8. Inability to attend group treatment sessions. Additional exclusion criteria for the study of biomarkers (50% of subjects in each branch): 1. Cold/infection symptoms on the day of blood collection. 2. Needle phobia. 3. BMI > 36 kg/m2 or weight > 110 kg 4. Consumption > 8 units of caffeine per day (maximum 1 drink with caffeine on the day of testing). 5. Smoker > 5 cigarettes a day. 6. Being pregnant or breastfeeding |
Резултат
Първични изходни мерки
1. Aggregate score of the Physical Function, Body Pain and Vitality subscales of the SF-36 [Through study completion, an average of 1 year]
Вторични изходни мерки
1. Numerical pain scale [Through study completion, an average of 1 year]
2. Hospital Anxiety and Depression Scale (HADS) [Through study completion, an average of 1 year.]
3. Pain Catastrophising Scale (PCS) [Through study completion, an average of 1 year]
Други изходни мерки
1. Psychological Inflexibility in Pain Scale (PIPS) [Through study completion, an average of 1 year]
2. EuroQoL (EQ-5D-5L) [Through study completion, an average of 1 year]
3. Behavioral Activation for Depression Scale (BADS) - short-form [Through study completion, an average of 1 year]
4. Credibility/Expectancy questionnaire (CEQ) [Baseline]
5. Client Service Receipt Inventory (CSRI) [Through study completion, an average of 1 year]
6. Adverse effects of treatments [Through study completion, an average of 1 year]
7. The Pain Monitor® app [Through study completion, an average of 1 year]
8. Socio-demographic questionnaire [Baseline]
9. Patient Health Questionnaire (PHQ-9) [Baseline]
